← Back to Search

Ultrasound Therapy

Transcranial MRgFUS for Movement Disorders

Waitlist Available
Led By Andres Lozano, MD
Research Sponsored by InSightec
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men and women, between 18 and 85 years, inclusive
A movement disorder symptom that has been deemed treatment-refractory by a movement disorder neurologist, including: akathisia, akinesia, athetosis, bradykinesia, chorea, dystonia, tremor, myoclonus, dyskinesia, spasms, tics
Screening 3 weeks
Treatment Varies
Follow Up at the time of exablate procedure
Awards & highlights

Study Summary

This trial will test whether a new MRI-guided procedure can help people with hard-to-treat movement disorders by targeting areas of the brain responsible for the symptoms.

Eligible Conditions
  • Tardive Dyskinesia
  • Wilson's Disease
  • Parkinson's Disease
  • Holmes Tremor
  • Essential Tremor
  • Movement Disorders
  • Huntington's Disease
  • Dystonia
  • Orofacial Dyskinesia

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
People who are between 18 and 85 years old, including both men and women.
You have a movement disorder that has not improved with treatment, as confirmed by a movement disorder specialist.
You have tried the standard treatments for movement disorders recommended by a specialist doctor and they didn't work for you.
You can tell the doctor how you feel during the ExAblate Neuro treatment.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the time of exablate procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the time of exablate procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Severity of Device and Procedure Related Complications

Trial Design

1Treatment groups
Experimental Treatment
Group I: Transcranial ExAblate SystemExperimental Treatment1 Intervention
Transcranial ExAblate System (MRgFUS)

Find a Location

Who is running the clinical trial?

InSightecLead Sponsor
88 Previous Clinical Trials
3,694 Total Patients Enrolled
Andres Lozano, MDPrincipal InvestigatorSunnybrook Health Sciences Centre
1 Previous Clinical Trials
10 Total Patients Enrolled

Media Library

ExAblate Transcranial MRgFUS (Ultrasound Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02252380 — N/A
Tardive Dyskinesia Research Study Groups: Transcranial ExAblate System
Tardive Dyskinesia Clinical Trial 2023: ExAblate Transcranial MRgFUS Highlights & Side Effects. Trial Name: NCT02252380 — N/A
ExAblate Transcranial MRgFUS (Ultrasound Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02252380 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What criteria are necessary for a person to qualify for this research endeavor?

"Eligible patients must present with etat marbre and be situated between 18-85 years old. The number of participants currently being recruited is approximately 10 individuals."

Answered by AI

Are those over twenty years of age eligible for participation in this research trial?

"This trial is specifically intended for those aged 18 to 85. Those younger than 18 have access to 50 studies, while 623 trials cater to people over the age of 65."

Answered by AI

Is this research currently accepting new participants?

"Per the data on clinicaltrials.gov, this investigation is not actively searching for test subjects at present. Initially posted in May of 2015 and last updated in December 2022 - while no longer accepting new participants, 637 other trials are currently welcoming volunteers."

Answered by AI
~1 spots leftby Apr 2025